When Compared to Other Atypical Antipsychotics, Fewer Schizophrenia Patients Who Take Zyprexa in the First Line Progress t

Decision Resources Unveils New Online Platform for Its Treatment Algorithms Service

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that relatively few patients who are prescribed Eli Lilly’s Zyprexa first line for the treatment of schizophrenia progress to second-line therapy within 360 days. According to Treatment Algorithms in Schizophrenia, among recently treated patients, only 36 percent of those taking Zyprexa progress to second-line therapy compared to much larger percentages for risperidone, AstraZeneca’s Seroquel and Bristol-Myers Squibb’s Abilify. Zyprexa is perceived to be one of the most effective antipsychotics in the treatment of schizophrenia.

The analysis also finds among newly diagnosed patients, more than 50 percent of diagnosed patients treated in the first year move from first-line to second-line therapy, and more than 60 percent of diagnosed patients on second-line therapy move to third-line therapy in the first year of treatment.

“Efficacy and tolerability of antipsychotics in schizophrenic patients can be unpredictable, so we see a significant percentage of patients switching to the next line of therapy within a year of diagnosis,” said Decision Resources Analyst Anne-Elise Tobin, Ph.D. “Additionally, polypharmacy is common in schizophrenia treatment, especially in later lines of therapy as physicians add agents to counter comorbidities and secondary symptoms caused antipsychotic therapies.”

Enhanced Service and Platform Now Available

The analysis is part of Decision Resources’ enhanced Treatment Algorithms Insight series, which features a new online platform. Interactive, user-friendly and with more graphical data views, the new platform enables users to easily toggle between diseases and time cohorts, which ultimately allows for more in-depth analysis on each line of therapy. Treatment Algorithms analysis is now updated quarterly to provide ongoing trending of product utilization by line of therapy and new therapy initiations. Through examination of U.S. patient-level claims data, Decision Resources’ Treatment Algorithms Insight series provides exceptional insight into physicians’ prescribing trends, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Mental Health  Pharmaceutical  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.